These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26956150)

  • 1. Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.
    Eyre TA; Linton KM; Rohman P; Kothari J; Cwynarski K; Ardeshna K; Bailey C; Osborne WL; Rowntree C; Eden D; Shankara P; Eyre DW; Jasani P; Chaidos A; Collins GP; Hatton CS
    Br J Haematol; 2016 Jun; 173(6):896-904. PubMed ID: 26956150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry.
    Zinzani PL; Bregni M; Spione M; Mitterer M; Musuraca G; Bugli A; Piazza F; Pinto A
    Acta Haematol; 2021; 144(3):259-263. PubMed ID: 33040061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
    Sancho JM; Navarro B; Soler Campos JA; de Oteyza JP; de Barrenetxea Lekue C; Bregni M; Grasso Cicala S; Spione M; Mombiedro C; Soler B; Zinzani PL
    Eur J Haematol; 2020 May; 104(5):499-508. PubMed ID: 31997425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.
    Herbrecht R; Cernohous P; Engert A; Le Gouill S; Macdonald D; Machida C; Myint H; Saleh A; Singer J; Wilhelm M; van der Jagt R
    Ann Oncol; 2013 Oct; 24(10):2618-2623. PubMed ID: 23946328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone.
    Cencini E; Rocco M; Ghio F; Simonetti F; Cuccaro A; De Marco F; Consoli C; Bocchia M; Fabbri A
    Eur J Haematol; 2023 Aug; 111(2):247-253. PubMed ID: 37161912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pixantrone in patients with relapsed/refractory diffuse large B-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional Tuscan Lymphoma network).
    Cencini E; Mecacci B; Rocco M; Innocenti F; Ghio F; Puccini B; Della Seta R; Simonetti F; Mannelli L; Cuccaro A; Bocchia M; Fabbri A
    Eur J Haematol; 2022 May; 108(5):383-390. PubMed ID: 35051301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma.
    Novakovic A; Boltezar L; Novakovic BJ
    Oncol Lett; 2020 Mar; 19(3):2028-2034. PubMed ID: 32194699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.
    Pettengell R; Sebban C; Zinzani PL; Derigs HG; Kravchenko S; Singer JW; Theocharous P; Wang L; Pavlyuk M; Makhloufi KM; Coiffier B
    Br J Haematol; 2016 Sep; 174(5):692-9. PubMed ID: 27118109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
    Pettengell R; Coiffier B; Narayanan G; de Mendoza FH; Digumarti R; Gomez H; Zinzani PL; Schiller G; Rizzieri D; Boland G; Cernohous P; Wang L; Kuepfer C; Gorbatchevsky I; Singer JW
    Lancet Oncol; 2012 Jul; 13(7):696-706. PubMed ID: 22652183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.
    Pettengell R; Coiffier B; Egorov A; Singer J; Sivcheva L
    Clin Drug Investig; 2018 Jun; 38(6):527-533. PubMed ID: 29564722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
    Hess G; Hüttmann A; Witzens-Harig M; Dreyling MH; Keller U; Marks R; Ernst T; Pott C; Viardot A; Frontzek F; Trautmann M; Ruckes C; Deuster O; Rosenwald A; Theobald M; Lenz G
    Br J Haematol; 2022 Aug; 198(3):482-491. PubMed ID: 35362552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
    Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
    Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
    Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pixantrone maleate for non-Hodgkin's lymphoma.
    Mukherji D; Pettengell R
    Drugs Today (Barc); 2009 Nov; 45(11):797-805. PubMed ID: 20126672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
    Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pixantrone: novel mode of action and clinical readouts.
    Minotti G; Han H; Cattan V; Egorov A; Bertoni F
    Expert Rev Hematol; 2018 Jul; 11(7):587-596. PubMed ID: 29912583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Lim ST; Fayad L; Tulpule A; Modiano M; Cabanillas F; Laffranchi B; Allievi C; Bernareggi A; Levine AM
    Leuk Lymphoma; 2007 Feb; 48(2):374-80. PubMed ID: 17325899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
    Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma.
    Muszbek N; Kadambi A; Lanitis T; Hatswell AJ; Patel D; Wang L; Singer JW; Pettengell R
    Clin Ther; 2016 Mar; 38(3):503-15. PubMed ID: 26856929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.